SCOTTISH biotech companies are officially in strong health and experiencing a faster rate of growth than the rest of Europe - creating an ideal environment for dealmakers. The latest snapshot of the industry reports that 2006 was the year of the deal. Intense competition has created a robust environment with prospects of “unprecedented deal activity”. >>> Discuss This Story
